Abstract
Background and Objectives Strabismus, a misalignment of the eyes, is an important risk factor for amblyopia and visual impairment in the pediatric population. Several studies have reported an increased likelihood of strabismus in persons on the autism spectrum, but prevalence estimates in this group vary greatly.
Methods We searched multiple databases to identify peer-reviewed articles published in English through November 1, 2020 that provided estimates of strabismus prevalence in autistic individuals. Prevalence estimates were synthesized using Bayesian random-effects meta-analysis, and sensitivity analysis was also performed using only the subset of studies that recruited participants from non-ophthalmologic settings and identified strabismus using structured ocular exams. Bayesian meta-regression was used to assess potential moderators of prevalence across studies.
Results A total of 151 nonduplicate articles were screened, of which 22 were included in the meta-analysis (k=28 samples, nAUT=113,227). The meta-analytic point prevalence of strabismus in autistic individuals was 13.4% (95% CrI [8.3,19.4]), and sensitivity analysis produced a very similar estimate (14.0% [7.0,22.0], nAUT=581). Esotropia was the predominant subtype of strabismus reported, accounting for approximately 55% of cases. Reported prevalence rates were higher in younger samples (BF10=13.43, R2Het =0.273) and samples recruited from optometry/ophthalmology clinics (BF10=11.47, R2Het =0.238).
Conclusion This meta-analysis found a high prevalence of strabismus in autistic individuals, with rates 3–10 times that of the general population. As untreated strabismus is a major risk factor for amblyopia in young children, these findings underscore the importance of timely screening and assessment of ocular problems in persons on the autism spectrum.
What’s Known on This Subject Strabismus has been reported to be more prevalent in individuals on the autism spectrum, but estimates have been very imprecise, ranging from 3–84% across studies.
What This Study Adds This study performs the first quantitative synthesis of strabismus prevalence in over 100,000 autistic individuals, generating more precise estimates of the prevalence of strabismus in the autistic population. Factors contributing to the large differences between studies are also examined using meta-regression.
Competing Interest Statement
Zachary Williams has served as a consultant for Roche. He is also a family partner for the Autism Speaks Autism Care Network Vanderbilt site and a member of the autistic researcher review board of the Autism Intervention Research Network on Physical Health (AIR-P).
Funding Statement
This study was supported by National Institute of General Medical Sciences grant T32-GM007347, National Institute on Deafness and Other Communication Disorders grant F30-DC019510, and the Nancy Lurie Marks Family Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The meta-analysis was considered "non-human subjects research" and was therefore exempt from IRB approval.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest Disclosures (includes financial disclosures): Zachary Williams has served as a consultant for Roche. He is also a family partner for the Autism Speaks Autism Care Network Vanderbilt site and a member of the autistic researcher review board of the Autism Intervention Research Network on Physical Health (AIR-P).
Funding/Support: This study was supported by National Institute of General Medical Sciences grant T32-GM007347, National Institute on Deafness and Other Communication Disorders grant F30-DC019510, and the Nancy Lurie Marks Family Foundation.
Role of Funder/Sponsor: No funding body or source of support had a role in the study design, data collection, analysis, or interpretation, decision to publish, or preparation of this article.
Data Availability
Original data used in the meta-analysis can be found in the primary articles, as well as supplemental table 1.
Abbreviations
- BF10
- Bayes factor comparing meta-regression model to baseline model
- CrI
- Highest-density credible interval
- DQ
- Developmental quotient
- IQ
- Intelligence quotient
- IQR
- Interquartile range
- Mdn
- Median
- nAUT
- Number of individuals diagnosed with autism in a study
- nStrabismus
- Number of autistic individuals diagnosed with strabismus in a study
- R2Het
- Proportion of heterogeneity explained by moderator
